Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
Patients with moderate-to-severe systemic lupus erythematosus (SLE) appear to fare well with anifrolumab, with a recent study showing that the drug has an acceptable long-term safety profile and helps maintain reductions in disease activity and glucocorticoid usage.
Anifrolumab for SLE shows favourable benefit–risk profile in extension study
22 Nov 2022
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
A significant number of patients with infective endocarditis have been found to have antineutrophil cytoplasmic antibody (ANCA), which is associated with longer disease duration, more frequent purpura, and kidney involvement, results of a study has shown.
ANCA-positive infective endocarditis tied to longer disease duration, kidney injury
22 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
22 Nov 2022
Inflammatory bowel disease may cause psoriasis, psoriatic arthritis
Inflammatory bowel disease appears to be a causal risk factor for both psoriasis and psoriatic arthritis, with Crohn’s disease specifically associated with the development of the two psoriasis outcomes, according to a study.
Inflammatory bowel disease may cause psoriasis, psoriatic arthritis
22 Nov 2022
TB rates elevated after ART initiation in PLHIV
People living with HIV (PLHIV) who initiate antiretroviral therapy (ART) are at an increased risk of developing tuberculosis (TB), particularly in the first 3 months after starting ART, according to a study presented at HIV Glasgow 2022.
